Loxo Sustainability Profile
Loxo Oncology, a prominent player in the biopharmaceutical industry, is headquartered in the United States and focuses on the development of targeted therapies for cancer treatment. Founded in 2013, the company has made significant strides in precision medicine, particularly in the field of oncology, with a commitment to addressing unmet medical needs. Loxo Oncology is renowned for its innovative approach to drug development, offering unique therapies that target specific genetic mutations in tumours. Their core products, including the well-regarded Vitrakvi (larotrectinib), exemplify their dedication to personalised medicine, setting them apart in a competitive market. With a strong presence in the US and expanding operations globally, Loxo has established itself as a leader in the oncology sector, achieving notable milestones in clinical trials and regulatory approvals.
DitchCarbon Score
How does Loxo's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Loxo's score of 52 is higher than 68% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Loxo Oncology, Inc., headquartered in the US, currently does not report specific carbon emissions data for the latest year, as indicated by the absence of emissions figures. However, the company is part of a corporate family relationship with Eli Lilly and Company, from which it inherits emissions data and climate initiatives. As a current subsidiary of Eli Lilly and Company, Loxo's climate commitments and reduction initiatives are aligned with those of its parent organisation. Eli Lilly has set ambitious targets to reduce its carbon footprint, focusing on Scope 1 and Scope 2 emissions, while also addressing Scope 3 emissions through various sustainability initiatives. Although specific reduction targets for Loxo are not detailed, the overarching commitments from Eli Lilly include participation in the Science Based Targets initiative (SBTi) and other climate pledges aimed at achieving significant reductions in greenhouse gas emissions. These initiatives reflect a commitment to sustainability and responsible environmental stewardship within the pharmaceutical industry. In summary, while Loxo Oncology does not provide specific emissions data, it is actively engaged in climate commitments through its relationship with Eli Lilly and Company, which sets a framework for emissions reduction and sustainability efforts.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 502,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 1,310,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | 200,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | - |
How Carbon Intensive is Loxo's Industry?
How Carbon Intensive is Loxo's Location?
Loxo's Scope 3 Categories Breakdown
Loxo's Scope 3 emissions, which increased by 62% last year and increased significantly since 2007, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 60% of Scope 3 emissions.
Top Scope 3 Categories
Loxo's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Loxo has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
